Cell and gene therapies continue to gain significant traction in the biopharmaceutical world. While this technology continues to grow, challenges will inevitably follow. Explore considerations for aseptic fill/finish challenges.

The reason for the existence of the pharmaceutical world is simple – People need medicine. How you get that medicine to the patient is the big question. While many different facets of medicine were brought to light by the COVID-19 pandemic, possibly none were viewed as more important than the need for increased urgency when dealing with medicine that can save the life of a patient in need.

Small-scale aseptic filling presents a unique set of challenges. Learn what to look for when evaluating small-scale aseptic filling technology.

Automated Systems of Tacoma, LLC (AST), a leading provider of flexible aseptic filling systems, announces Josh Russell has rejoined AST as the Vice President of Sales & Marketing. Josh lives in Philadelphia, PA region and rejoins the AST team after three years at AES Clean Technologies as VP of Sales & Marketing. Previously, Josh worked at AST over a fifteen-year span holding several positions of responsibility including leading the development of AST’s fill-finish systems product line, and later as Vice President of Business Development.

The current and future wave of pharmaceutical and biotechnology products is making historical aseptic filling machine manufacturing methodologies inadequate and antiquated. Traditional production processes used for high-volume drug products are stressed to efficiently meet the production requirements of targeted medicines that dominate today’s clinical pipelines.

AST, a leading provider of flexible aseptic filling systems, announces they are now offering delivery of their most popular isolated equipment within 6 months of purchase. This is a dramatic improvement over typical industry delivery times, which are often up to 24 months. AST knows that time to market is critical in delivering drug products to sick patients, and quick delivery demonstrates their commitment to reducing the time it takes to provide critical treatments.

AST is excited to exhibit at Achema this month, August 22-26 in Frankfurt, Germany. Keith Dodson, Vice President of Global Business Development at AST, will be in Hall 3.1 Booth B32 To schedule a meeting with Keith Dodson during the show, reach out at https://www.ast-inc.com/contact-us/.

An aseptic filling and closing machine solution allowed Catalent to reliably process a wide range of both trayed and nested vials for their client product needs.

Industry experts weigh in on how to help 503(b) compounding facilities bring acute care drugs to market more quickly, provide a safer drug administration process and minimize health care and hospital costs.

Automated Systems of Tacoma, LLC (AST), a leading provider of flexible aseptic filling systems, announces the addition of two new members of the Business Development team. Drew Hoffman joins AST as Senior Director of Business Development serving customers in the Midwest and Southeast regions of the United States. Mico Holguin joins AST as Senior Director of Business Development serving customers in the United States West Coast and Pennsylvania.

Automated Systems of Tacoma, LLC (AST), a leading provider of flexible aseptic filling systems, and Quality Chemical Laboratories, LLC (QCL), a Contract Development and Manufacturing Organization (CDMO) announce their partnership on two multi-format filling and closing machines for use in cGMP aseptic small batch processing.

Small batch production will serve a critical role in the future of modern medicine. Learn more about maximizing process efficiency to reduce waste and improve yield for small batches of drug product.

Learn about implementing automated technologies like robotics to overcome growing issues with sterility assurance and data integrity.

Automated Systems of Tacoma, LLC (AST), a leading provider of flexible aseptic filling systems, and Goodwin Biotechnology, Inc. (Goodwin), a Contract Development and Manufacturing Organization (CDMO) announce their partnership on a GENiSYS C20 multi-format filling and closing machine for syringes, cartridges and vials.

We are proud to announce that AST president and CEO Joe Hoff will be a panelist in the upcoming webinar "Pharmaceutical industry: How robotics offer new answers to today's challenges," hosted by Staubli.

The upcoming 30-minute webinar presents an overview of the company’s mission and values, along with a detailed product overview highlighting how AST’s machines respond to the unique challenges found across a variety of filling applications.

Next generation drug products are more targeted and patient specific by nature causing batch sizes to be much smaller. This paradigm shift paves the way for more flexible manufacturing solutions.

The aim of advanced aseptic processing is the elimination and absolute control of all sources of contamination – most importantly, human generated contamination. Robotics and isolator barrier systems are core technologies in this endeavor.

Robotic aseptic fill finish equipment offers many benefits to modern facilities, including flexibility to adjust to future growth and the speed to market necessary for today’s changing industry.

This article describes how the advantages of a system that can streamline the tech transfer process by enabling efficient drug development activities and process data collection.

Josh Russell, VP of Sales & Marketing, describes the AST Quick Delivery program, which makes certain isolated fill finish equipment available within six months of purchase.

Join Keith Dodson of Automated Systems to discover small batch aseptic solutions for cell therapy, gene therapy, vaccines, R&D, biosimilars and CDMO’s.

The AST GENiSYS R provides ultimate flexibility for the aseptic filling of liquid pharmaceuticals. Designed with the specific challenges of small-batch production in mind, the GENiSYS R can be built to meet the needs of your facility today and for years to come. Learn more in our latest video.

The 4th generation GENiSYS C is an advanced yet compact solution for automated aseptic processing of liquid pharmaceutical products, with many features typically reserved for large scale filling lines. Learn more in our latest video.

This presentation addresses the changing needs for the manufacturing of biologics and the rationale for the use of robotics and automation in aseptic fill and finish processing of these products. 

ASEPTiCell provides flexible, robotic filling and finishing of vials, syringes and cartridges for small to medium clinical and commercial batches. The modular design allows the ASEPTiCell to be built to your specification without the cost and risk of customization.

The GENiSYS® R offers a unique blend of automated capabilities to ensure your sterile products are processed in strict accordance with cGMP requirements. With robotic handling available from bag opening to vial sealing, and integration with barrier technologies, your product is protected from contamination through all stages of processing. 

GENiSYS^® R provides ultimate flexibility for processing ready-to-use vials, syringes and cartridges on a single machine. Highly reliable robotics and recipe driven changeovers allow for complete format changes in as little as 30 minutes. Maximize productivity and return-on-investment with the GENiSYS R.

AST’s GENiSYS® Lab semi-automatic systems are ideal for drug product development and cGMP production applications. Each system automates the critical aseptic operations for vial, syringe and cartridge processing to reduce contamination risk and product variability. GENiSYS Lab offers a perfect balance between automated features, size and affordability without compromising quality, safety and ease of use.

Is the general opinion about robotics improving? Watch this webinar to learn more about where and how robotics add value and solve problems.